NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
(Total Views: 195)
Posted On: 11/19/2018 5:50:00 PM
NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Bria-IMT Clinical Data at San Antonio Breast Cancer Symposium
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatment options for cancer, this morning announced that its Bria-IMT will be featured in a poster session during this year’s San Antonio Breast Cancer Symposium (“SABCS”), to be held December 4-8, 2018, in San Antonio, Texas. The poster highlights data on Bria-IMT’s use as a monotherapy demonstrating positive proof-of-concept, as well as an initial safety and tolerability assessment for its use in combination with pembrolizumab [KEYTRUDA – manufactured by Merck & Co., Inc. (NYSE: MRK)] for advanced breast cancer. Thomas Jefferson University assistant professor of medical oncology and main principal investigator (PI) of the study Saveri Bhattacharya, DO, will present the poster. Copies of the abstract and the poster will be available on the company’s website following the presentation.
“Despite years of research and improved treatments for breast cancer, according to the latest figures by American Cancer Society, over 40,000 people are expected to die of breast cancer in the United States this year, presenting a large unmet medical need,” BriaCell President and CEO Dr. Bill Williams stated in the news release. “Several challenges need to be addressed, including improving efficacy, safety, and containing the cost of care. At BriaCell, we have been working to resolve all these issues. Bria-IMT has demonstrated positive proof-of-concept in advanced breast cancer, and we will delve into these data in San Antonio. We have firm grounds to believe the anti-tumor effects of Bria-IMT can be greatly improved by combination with KEYTRUDA. We are excited with the early clinical findings of this novel treatment approach and look forward to presenting our data.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatment options for cancer, this morning announced that its Bria-IMT will be featured in a poster session during this year’s San Antonio Breast Cancer Symposium (“SABCS”), to be held December 4-8, 2018, in San Antonio, Texas. The poster highlights data on Bria-IMT’s use as a monotherapy demonstrating positive proof-of-concept, as well as an initial safety and tolerability assessment for its use in combination with pembrolizumab [KEYTRUDA – manufactured by Merck & Co., Inc. (NYSE: MRK)] for advanced breast cancer. Thomas Jefferson University assistant professor of medical oncology and main principal investigator (PI) of the study Saveri Bhattacharya, DO, will present the poster. Copies of the abstract and the poster will be available on the company’s website following the presentation.
“Despite years of research and improved treatments for breast cancer, according to the latest figures by American Cancer Society, over 40,000 people are expected to die of breast cancer in the United States this year, presenting a large unmet medical need,” BriaCell President and CEO Dr. Bill Williams stated in the news release. “Several challenges need to be addressed, including improving efficacy, safety, and containing the cost of care. At BriaCell, we have been working to resolve all these issues. Bria-IMT has demonstrated positive proof-of-concept in advanced breast cancer, and we will delve into these data in San Antonio. We have firm grounds to believe the anti-tumor effects of Bria-IMT can be greatly improved by combination with KEYTRUDA. We are excited with the early clinical findings of this novel treatment approach and look forward to presenting our data.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)